SCHEMBL7559570

SCHEMBL7559570

Cn1[nH]cnc1=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11463496 0.68
SCHEMBL6126587 0.68
SCHEMBL30947244 0.58 HPGD (0.44)
SCHEMBL8340231 0.56
SCHEMBL17590232 0.56 ADORA2B (0.45)
SCHEMBL23948971 0.55
SCHEMBL2279912 0.54
SCHEMBL2918041 0.54
SCHEMBL13379874 0.53
SCHEMBL34471141 0.53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3233849-A1 HETEROARYLALKYLENE ARYL SULTAM DERIVATIVES AS RORc MODULATORS F. Hoffmann-La Roche AG (CH) 2017-10-25 EP claimed
WO-2016096936-A1 HETEROARYLALKYLENE ARYL SULTAM DERIVATIVES AS RORc MODULATORS F. HOFFMANN-LA ROCHE AG (CH) 2016-06-23 WO claimed
WO-1999011129-A1 ENANTIOMERICALLY ENRICHED COMPOSITIONS AND THEIR PESTICIDAL USE E.I. DU PONT DE NEMOURS AND COMPANY (US) 1999-03-11 WO claimed
US-12577217-B2 15-PGDH inhibitor KYORIN PHARMACEUTICAL CO., LTD. (JP) 2026-03-17 US disclosed
CN-116120285-A Heterocyclic compound, preparation method and application thereof 武汉人福创新药物研发中心有限公司 2023-05-16 CN disclosed
US-20230082516-A1 15-PGDH INHIBITOR KYORIN PHARMACEUTICAL CO., LTD. (JP) 2023-03-16 US disclosed
EP-3344619-A1 PHENOXYMETHYL DERIVATIVES H. Hoffnabb-La Roche Ag (CH) 2018-07-11 EP disclosed
WO-2017037146-A1 PHENOXYMETHYL DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2017-03-09 WO disclosed
US-20020137664-A1 Substituted piperidines as melanocortin-4 receptor agonists MERCK & CO., INC. 2002-09-26 US disclosed
US-6350760-B1 OBESITY, DIABETES, SEXUAL DYSFUNCTION; MERCK & CO., INC. 2002-02-26 US disclosed